Bibliography
Found 26 results
Filters: Keyword is AIDS Dementia Complex and Author is Letendre, Scott L [Clear All Filters]
Nuclear-Mitochondrial interactions influence susceptibility to HIV-associated neurocognitive impairment. Mitochondrion. 2019 ;46:247-255.
Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study. Am J Med Genet B Neuropsychiatr Genet. 2017 ;174(4):413-426.
Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. AIDS. 2017 ;31(10):1365-1378.
Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. J Infect Dis. 2016 ;213(7):1065-73.
HIV-associated neurocognitive disorder is associated with HIV-1 dual infection. AIDS. 2016 ;30(17):2591-2597.
Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment. PLoS One. 2016 ;11(6):e0157160.
Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res. 2016 ;14(4):324-30.
The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study. Clin Infect Dis. 2016 ;63(5):694-702.
. CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. J Neurovirol. 2015 ;21(5):559-67.
Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection. Clin Infect Dis. 2015 ;61(9):1476-84.
Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014 ;65(2):190-7.
. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013 ;19(2):150-6.
A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol. 2013 ;8(5):1123-35.
. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr. 2013 ;62(1):36-42.
Global NeuroAIDS roundtable. J Neurovirol. 2013 ;19(1):1-9.
A lipid storage-like disorder contributes to cognitive decline in HIV-infected subjects. Neurology. 2013 ;81(17):1492-9.
Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol. 2012 ;18(2):81-90.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009 ;15(2):187-95.
Frequency and predictors of self-reported prospective memory complaints in individuals infected with HIV. Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists [Internet]. 2007 ;22:187-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17289343
. Neurologic complications of HIV disease and their treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA [Internet]. 2007 ;15:32-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17485785
.